- Home
- CIGL vs TCRX Comparison
CIGL vs TCRX Comparison
Compare CIGL & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CIGL | TCRX |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Singapore | United States |
| Employees | 134 | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.8M | 63.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CIGL | TCRX |
|---|---|---|
| Price | $1.65 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 45.8K | ★ 526.7K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $69.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $1.40 | $0.88 |
| 52 Week High | $25.00 | $2.57 |
Technical Indicators
Market Signals| Indicator | CIGL | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 43.17 | 47.18 |
| Support Level | $1.52 | $0.92 |
| Resistance Level | $2.20 | $1.23 |
| Average True Range (ATR) | 0.13 | 0.08 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 25.00 |
Price Performance
Historical ComparisonAbout CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.